Published in J Virol on March 14, 2012
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity (2013) 2.17
Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A (2012) 2.13
Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog (2013) 1.65
Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection. Cell (2015) 1.55
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol (2015) 1.35
HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol (2012) 1.30
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J Virol (2013) 1.13
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell (2016) 1.10
Broadly neutralizing antibodies developed by an HIV-positive elite neutralizer exact a replication fitness cost on the contemporaneous virus. J Virol (2012) 1.06
HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J Virol (2015) 1.02
Virological features associated with the development of broadly neutralizing antibodies to HIV-1. Trends Microbiol (2015) 1.00
Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides. Antimicrob Agents Chemother (2013) 1.00
Distinct evolutionary pressures underlie diversity in simian immunodeficiency virus and human immunodeficiency virus lineages. J Virol (2012) 1.00
Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. J Virol (2015) 0.98
Sequential evolution and escape from neutralization of simian immunodeficiency virus SIVsmE660 clones in rhesus macaques. J Virol (2012) 0.95
Coverage of primary mother-to-child HIV transmission isolates by second-generation broadly neutralizing antibodies. AIDS (2013) 0.93
A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01. J Biol Chem (2012) 0.87
Strategies to guide the antibody affinity maturation process. Curr Opin Virol (2015) 0.87
HIV-1 gp120 as a therapeutic target: navigating a moving labyrinth. Expert Opin Ther Targets (2015) 0.86
Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. PLoS One (2012) 0.85
Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. Immunity (2016) 0.85
Broadly Neutralizing Antibodies for HIV Eradication. Curr HIV/AIDS Rep (2016) 0.84
Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. J Virol (2015) 0.83
HIV antibodies for treatment of HIV infection. Immunol Rev (2017) 0.80
Human immunodeficiency virus type-1 (HIV-1) continues to evolve in presence of broadly neutralizing antibodies more than ten years after infection. PLoS One (2012) 0.80
Effects of Darwinian Selection and Mutability on Rate of Broadly Neutralizing Antibody Evolution during HIV-1 Infection. PLoS Comput Biol (2016) 0.79
Approaches to preventative and therapeutic HIV vaccines. Curr Opin Virol (2016) 0.79
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection. Curr Opin HIV AIDS (2015) 0.77
Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Rep (2016) 0.76
Structure of an N276-Dependent HIV-1 Neutralizing Antibody Targeting a Rare V5 Glycan Hole Adjacent to the CD4 Binding Site. J Virol (2016) 0.76
CD4 binding determinant mimicry for HIV vaccine design. Front Immunol (2012) 0.76
An HIV gp120-CD4 Immunogen Does Not Elicit Autoimmune Antibody Responses in Cynomolgus Macaques. Clin Vaccine Immunol (2016) 0.76
Survivors Remorse: antibody-mediated protection against HIV-1. Immunol Rev (2017) 0.75
Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. J Virol (2016) 0.75
Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System. Curr HIV/AIDS Rep (2017) 0.75
The HIV Genomic Incidence Assay Meets False Recency Rate and Mean Duration of Recency Infection Performance Standards. Sci Rep (2017) 0.75
Potent In Vivo NK Cell-mediated Elimination of HIV-1-Infected Cells Mobilized by a gp120-bispecific and Hexavalent Broadly Neutralizing Fusion Protein. J Virol (2017) 0.75
Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop. Immunity (2017) 0.75
MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res (2004) 168.89
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
MODELTEST: testing the model of DNA substitution. Bioinformatics (1998) 101.19
MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics (2004) 50.89
The rapid generation of mutation data matrices from protein sequences. Comput Appl Biosci (1992) 44.38
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea. J Mol Evol (1989) 16.24
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science (1998) 12.52
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature (2007) 11.73
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Dendroscope: An interactive viewer for large phylogenetic trees. BMC Bioinformatics (2007) 11.03
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Timing the ancestor of the HIV-1 pandemic strains. Science (2000) 10.42
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
A Hidden Markov Model approach to variation among sites in rate of evolution. Mol Biol Evol (1996) 8.35
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. Science (1992) 7.44
Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol (2008) 7.14
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One (2010) 5.73
A simulation comparison of phylogeny algorithms under equal and unequal evolutionary rates. Mol Biol Evol (1994) 5.26
Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis (2005) 5.14
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Gender differences in HIV-1 diversity at time of infection. Nat Med (2000) 4.69
A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. PLoS Pathog (2010) 4.47
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol (2011) 4.18
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 4.13
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Detecting hypermutations in viral sequences with an emphasis on G --> A hypermutation. Bioinformatics (2000) 3.07
Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol (2006) 2.95
Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure (2008) 2.74
Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog (2009) 2.70
HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses (2002) 2.68
Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol (2001) 2.53
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. J Virol (2006) 2.41
Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog (2009) 2.34
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol (2007) 2.29
Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS Pathog (2009) 2.29
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J Virol (2011) 2.26
Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16
Mechanism of human immunodeficiency virus type 1 resistance to monoclonal antibody B12 that effectively targets the site of CD4 attachment. J Virol (2009) 1.88
Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. J Virol (2008) 1.80
Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol (2009) 1.78
Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus. Virology (1991) 1.67
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol (2001) 1.53
The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol (2010) 1.49
Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathog (2011) 1.47
Recombination Analysis Tool (RAT): a program for the high-throughput detection of recombination. Bioinformatics (2004) 1.27
HIV-1 envelope subregion length variation during disease progression. PLoS Pathog (2010) 1.20
Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity. J Virol (2011) 1.12
Temporal analysis of HIV envelope sequence evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody response. Virology (2010) 0.95
Antibody neutralization and escape by HIV-1. Nature (2003) 21.48
HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood (2006) 17.38
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol (2005) 15.61
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother (2002) 13.91
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol (2002) 10.37
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature (2009) 9.51
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science (2006) 7.12
Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med (2007) 7.12
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood (2002) 6.73
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat Med (2009) 6.14
Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science (2006) 6.06
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol (2009) 5.91
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity (2008) 5.86
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis (2006) 5.53
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol (2004) 5.29
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol (2008) 4.73
Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med (2005) 4.68
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol (2003) 4.49
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol (2007) 4.45
Dynamics of HIV-1 recombination in its natural target cells. Proc Natl Acad Sci U S A (2004) 4.37
Origin of the human malaria parasite Plasmodium falciparum in gorillas. Nature (2010) 4.35
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science (2009) 4.20
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog (2009) 4.04
T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol (2004) 4.02
Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature (2010) 3.96
HIV vaccine research: the way forward. Science (2008) 3.86
Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol (2009) 3.85
Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol (2008) 3.83
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity (2012) 3.77
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Avidity for antigen shapes clonal dominance in CD8+ T cell populations specific for persistent DNA viruses. J Exp Med (2005) 3.63
Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe (2009) 3.58
Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med (2004) 3.48
Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis (2006) 3.40
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol (2010) 3.40
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36